These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27283043)

  • 1. Effects of nucleos(t)ide analogs on body composition in HBV-infected men: An age- and BMI-matched, cross-sectional study.
    Yao J; Zhou L; Hua X; Kong M; Chen Y; Duan Z
    Nutrition; 2016; 32(11-12):1206-10. PubMed ID: 27283043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
    Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
    Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
    Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
    Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
    Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects.
    Wong GL; Tse YK; Wong VW; Yip TC; Tsoi KK; Chan HL
    Hepatology; 2015 Sep; 62(3):684-93. PubMed ID: 25973979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B.
    Wei L; Kao JH
    Curr Med Res Opin; 2017 Mar; 33(3):495-504. PubMed ID: 27882776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    Papatheodoridis GV
    Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
    Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy.
    Madeddu G; Ortu S; Garrucciu G; Maida I; Melis M; Muredda AA; Mura MS; Babudieri S
    J Med Virol; 2017 Jul; 89(7):1208-1214. PubMed ID: 27922198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China.
    Qi X; Wang JY; Mao RC; Zhang JM
    J Viral Hepat; 2015 Jan; 22(1):46-54. PubMed ID: 25402626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
    Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.
    Wang Y; Xiang X; Chen L; Cao Z; Bao R; Zhou H; Tang W; Lu J; Lin L; Xie Q; Bao S; Wang H
    Oncotarget; 2016 Sep; 7(36):58553-58562. PubMed ID: 27329718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is it possible to stop treatment with nucleos(t)ide analogs in patients with e-antigen negative chronic hepatitis B? Experience and new expectations].
    Martín Mateos RM; Moreira Vicente VF; Tavío Hernández E; Cuño Roldán JL; Téllez Villajos L; Aicart Ramos M; Arribas Anta J; Zaera de la Fuente C; Albillos Martínez A
    Gastroenterol Hepatol; 2015 May; 38(5):305-12. PubMed ID: 25636371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
    Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
    J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review.
    de Fraga RS; Van Vaisberg V; Mendes LCA; Carrilho FJ; Ono SK
    J Gastroenterol; 2020 May; 55(5):496-514. PubMed ID: 32185517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China.
    Qian F; Qin J; Li D; Ma Z; Zhang H; Jin F; Wang W
    J Infect Dev Ctries; 2016 Sep; 10(9):996-1002. PubMed ID: 27694733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biomarkers of renal impairment and their application in renal function monitoring during treatment with nucleos(t)ide analogues].
    Li HS; Ma H
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):234-6. PubMed ID: 27095771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B.
    Carey I; Byrne R; Childs K; Horner M; Bruce M; Wang B; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Oct; 25(10):1139-1150. PubMed ID: 29660209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.